Combination of potential biomarkers may help predict response to immunotherapy in kidney cancer
Currently, it is difficult for clinicians to decide which patients [...]
Currently, it is difficult for clinicians to decide which patients [...]
Nivolumab was the first immunotherapy to be approved for the [...]
In a paper published in Clinical Genitourinary Cancer the link [...]
Results from the phase II FRACTION-RCC clinical trial to assess [...]
Two studies were presented during the 2020 American Society of [...]
Results from the pivotal phase 3 CheckMate-9ER clinical trial evaluating [...]
Nivolumab alone and in combination with ipilimumab is used for [...]
Two small studies reported on patients whose kidney cancer had [...]
The results from one of the first clinical trials of [...]
Five-year follow-up results from the phase 3 CheckMate-025 study, which [...]